for patenting, so that continued faith in patents constitutes a kind of irrational adherence to myth or falsehood. While … institutional sociology: firms patent because other firms patent, because investors expect them to patent, and because patents … inefficiency of patents …

Patents in the life sciences sector have sparked considerable debate over the past years. The grant of a series of … patents for the screening of breast cancer (BRCA) genes led to wide controversy in Europe, the US and Australia. The grant of … patents for plants resulting from essentially biological processes, also spurred stormy disputes. Decisions on the scope of …

We have examined all the US patents (444) issued to homegrown Indian pharma and pharma biotech firms. Most (425, 95 …%) patents are pharma patents not biotech (19). Also, only 11 patents have been cited ten times or more. This data provides one …

In the ongoing debate concerning DNA patents, there is a need for empirical data. We aim at treating this data set for … DNA patents related to diagnostic genetic testing. To this end we developed two tools to facilitate this process. First …, we set up a search strategy to find the relevant patents. Second, we provide a claim classification template to assist …

The genetics community is increasingly concerned that patents might lead to restricted access to research and health …

, and receiving investment and being acquired. I further find that the number of patents (and not merely the fact that a … company has patents or not) contributes to higher total funding. I finally observe that patenting early is also associated to … also conclude that while more patents are associated with higher funding, patents account for a relevant but small portion …

inventions. Instead it uses its patents offensively and actively to block its competitors …